How Medical Device Classification Works

By Kevin Fernando · Sep 17, 2026 · 8 min read

Medical device classification is an FDA system that assigns devices to one of three classes based on the risk they pose and the regulatory controls needed to ensure safety. Class I devices face general controls only; Class II devices require special controls and predicate comparison; Class III devices require premarket approval. The FDA has classified approximately 1,700 different generic device types across 16 medical specialties.

Medical device classification is not an arbitrary sorting system. It is a regulatory framework that determines what evidence a manufacturer must gather, what testing it must conduct, and what approval process it must navigate before a device can be sold in the United States. The FDA has established classifications for approximately 1,700 different generic types of devices, grouped into 16 medical specialties. Each device is assigned to one of three classes based on a single principle: the level of control necessary to assure the device's safety and effectiveness.

Understanding which class a device falls into is essential for anyone involved in device development, regulation, or market access. The classification determines not just the timeline to market, but the depth of evidence required, the types of testing mandated, and whether the device can be marketed at all without explicit FDA approval before sale.

What FDA medical device classification is

Medical device classification is the FDA's system for assigning regulatory requirements to devices based on the risk they pose to patients and users. Each of the three classes represents a different level of regulatory oversight. The classification system exists because not all devices pose the same risk. A tongue depressor and an implantable pacemaker are both medical devices, but they require vastly different levels of scrutiny before they can be sold.

The classification determines which regulatory pathway a device must follow. That pathway dictates what the manufacturer must prove, how much testing is required, and whether the FDA must review and clear the device before it enters the market. In this sense, classification is not a label applied after the fact; it is the determinant of the entire regulatory journey.

Why classification matters

Classification matters because it determines the regulatory controls that will apply to a device throughout its life cycle. A device in a lower class faces fewer barriers to market entry and lower ongoing compliance costs. A device in a higher class faces more rigorous review, longer timelines, and more extensive evidence requirements.

The stakes are concrete. A Class I device may be able to reach patients with minimal premarket review. A Class II device must prove it is substantially equivalent to an existing device and typically waits months for FDA clearance. A Class III device must undergo premarket approval, a process that can take years and requires clinical trial data demonstrating safety and effectiveness. For a manufacturer, classification determines feasibility, cost, and time to revenue. For patients, it determines how much evidence the FDA has reviewed before the device is available to them.

Class I: General controls only

Class I devices are those for which general controls alone are sufficient to provide reasonable assurance of safety and effectiveness. General Controls are the basic regulatory authorities established in the Medical Device Amendments that provide the FDA with the means to regulate devices. Class I is the least stringent of the three classes.

Class I devices have low potential for harm and are not intended to support or sustain life. They are subject to general controls such as good manufacturing practices and proper labeling, but most are exempt from premarket notification requirements. General Controls apply to all three device classes, but for Class I devices, they are the only level of control required. These general provisions include requirements related to device registration and listing, good manufacturing practices, labeling, records and reports, and notification procedures. A tongue depressor, a stethoscope, and a manual wheelchair are examples of Class I devices. The regulatory burden is minimal because the risk is minimal.

Class II: Special controls and predicate comparison

Class II devices are those for which general controls alone are insufficient and for which special controls are necessary to mitigate risks. Over 40% of all medical devices fall into the Class II category, making it the largest group.

Class II devices are subject to both general controls and special controls. Special controls are additional regulatory mechanisms designed to address the specific risks posed by the device. They can take the form of performance standards, postmarket surveillance requirements, patient registries, or specific labeling requirements. Class II devices include powered wheelchairs, infusion pumps, surgical drapes, blood pressure cuffs, and diagnostic imaging software.

Most Class II devices require submission of a premarket notification, commonly called a 510(k). The 510(k) is a premarketing submission made to the FDA to demonstrate that the device to be marketed is safe and effective by proving substantial equivalence to a legally marketed device, called a predicate device. The goal is to demonstrate that the device is substantially equivalent to a device already cleared by the FDA and in commercial distribution. This comparison-based approach allows the FDA to clear Class II devices without requiring new clinical trials for every similar device. Current FDA processing times for 510(k) submissions average 142 days.

Class III: Premarket approval pathway

Class III devices are those that support or sustain human life, are of substantial importance in preventing impairment of human health, or which present a potential, unreasonable risk of illness or injury. Only 10% of medical devices marketed in the U.S. fall under the Class III category.

Class III devices are reserved for technologies that sustain or support life, are implanted in the human body, or pose a significant potential for harm if they malfunction. Examples include implantable pacemakers and deep brain stimulators. Because of the level of risk associated with Class III devices, the FDA has determined that general and special controls alone are insufficient to assure safety and effectiveness. Therefore, almost all Class III devices require premarket approval (PMA) from the FDA before being marketed.

Premarket approval is the FDA process of scientific and regulatory review to evaluate the safety and effectiveness of Class III medical devices. It is the most rigorous approval pathway. The regulation governing premarket approval is located in Title 21 Code of Federal Regulations Part 814. The PMA process typically requires clinical trial data, manufacturing information, and a comprehensive demonstration that the device's benefits outweigh its risks. This is why Class III devices take the longest to bring to market and why they carry the highest development costs.

How the FDA determines which class a device belongs in

The FDA uses a systematic process to assign devices to their appropriate class. The process centers on two key factors: what the device is intended to do and what risks it poses. Device classification depends on the intended use of the device and also upon indications for use. A device's physical form is less important than its function and the claims made about what it will do.

The FDA has established classifications for approximately 1,700 different generic types of devices across 16 medical specialty panels. Each generic type is assigned to one of the three classes based on the level of control necessary to assure safety and effectiveness. When a manufacturer develops a new device, it must determine which of these 1,700 generic types its device most closely resembles, and thus which class it falls into.

Intended use and risk assessment

The FDA evaluates what a device is intended to do and what harm it could cause if it malfunctions or is used incorrectly. Intended use is not what the device might be used for in practice; it is what the manufacturer claims it will do, as stated in labeling and marketing materials. The FDA also considers the indications for use, which are the diseases or conditions the device is intended to diagnose, treat, cure, mitigate, or prevent.

Based on intended use and indications, the FDA assesses the risk. A device intended to measure blood pressure on the arm poses less risk than a device intended to deliver electrical current to the heart. A diagnostic device that provides information poses less risk than a therapeutic device that intervenes in the body. The risk assessment considers both the severity of harm if something goes wrong and the probability that something will go wrong. A device that, if it fails, could cause death or serious injury is classified higher than a device whose failure would cause minor inconvenience.

Existing controls and precedent

The FDA does not classify devices in isolation. It looks at whether existing regulatory controls are sufficient or whether new ones are needed. If general controls alone have proven adequate to ensure safety and effectiveness for similar devices over time, a new device in that category may also fall into Class I. If general controls have proven insufficient and special controls have been developed to address specific risks, a new device may fall into Class II. If no existing controls, special or general, have proven sufficient, the device is assigned to Class III and requires premarket approval.

Precedent matters because the FDA builds on what it has learned. If the agency has cleared dozens of similar devices through the 510(k) pathway and they have performed safely in the market, it is reasonable to assume that a substantially equivalent new device will also be safe. If a device type has caused problems in the market or if clinical evidence shows that special oversight is needed, the FDA may assign new devices in that category to a higher class or impose special controls. The classification system is not static; it reflects the accumulated experience of the FDA and the medical device industry.

When classification changes or requires clarification

A device's classification can be unclear or may shift based on how it is marketed. If a manufacturer makes claims about a device that go beyond its intended use, the device may be reclassified into a higher category. For example, a topical cream marketed as a moisturizer might be classified as a cosmetic with minimal oversight. If the same cream is marketed with claims that it treats a skin condition, it becomes a drug or device and faces different regulatory requirements.

Manufacturers sometimes seek clarification from the FDA about how a device should be classified before investing in development and testing. The FDA can issue guidance or formal classification determinations. If a device's classification is genuinely ambiguous, a manufacturer can request a formal classification from the FDA, which will review the device's intended use, risks, and the adequacy of existing controls to determine the appropriate class. This process ensures that devices are not misclassified and that manufacturers understand their regulatory obligations before committing resources to a particular pathway.

Do this automatically

Determining the correct FDA classification for a new medical device requires reviewing regulatory guidance documents, analyzing predicate devices, and documenting risk assessments, a process that can consume weeks of specialized expertise per submission, multiplied across the dozens of devices most manufacturers develop in their pipeline. Software platforms can systematize this classification workflow by organizing regulatory requirements, predicate comparisons, and risk documentation in a structured format that reduces manual research and coordination time. Healthcare research reads ClinicalTrials.gov records, regulatory filings, and published literature directly, and cites each claim to the record it came from, across as many subjects as you need, with Mimir attaching a citation to every figure. It will not predict a trial's outcome or advise on anyone's treatment. Those decisions stay with clinicians and regulators, and deliberately so. Every plan includes it, including the free one.

Start your first report and run it on something you already know well.

This article is general information about healthcare and life-sciences topics. It is not medical advice, diagnosis, or treatment guidance, and it is not a substitute for a qualified professional. Any treatment decision should be discussed with a clinician.